



04-03-03

#22, RCE/Goigak/100

Express Mail Mailing Label No. EL953994379US

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

ADDRESS TO: Box RCE Assistant Commissioner for Patents Washington, D.C. 20231	Application No.	09/292,217
	Filing Date	April 15, 1999
	First Named Inventor	Gillies
	Group Art Unit	1644
	Examiner Name	Roark, Jessica H.
	Attorney Docket No.	LEX-004

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

NOTES

RCE v. CPA: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53(d) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA.

FEE AND SUBMISSION REQUIRED: A submission as used in this section includes, but is not limited to, an information disclosure statement, an amendment to the written description, claims, or drawings, new arguments, or new evidence in support of patentability. If reply to an Office action under 35 U.S.C. 132 is outstanding, the submission must meet the reply requirements of § 1.111 (see 37 C.F.R. 1.114 (c)).

RCE APPLIES TO: An application in which prosecution is closed (see 37 C.F.R. § 1.114 (b)).

RCE DOES NOT APPLY TO: (1) A provisional application; (2) an application for a utility or plant patent filed under 35 U.S.C. 111(a) before June 8, 1995; (3) an international application filed under 35 U.S.C. 363 before June 8, 1995; (4) an application for a design patent; or (5) a patent under reexamination (see 37 C.F.R. 1.114(e)).

1. SUBMISSION REQUIRED UNDER 37 C.F.R. § 1.114

- a. Enter and consider the unentered amendment under 37 C.F.R. § 1.116 previously filed on ____.
- b. Consider the arguments in the Appeal Brief or Reply Brief previously filed on ____.
- c. Amendment/Response enclosed.
- d. Affidavit(s)/Declaration(s) enclosed.
- e. Information Disclosure Statement (IDS) enclosed.
 - i. PTO-1449
 - ii. Copies of IDS Citations
- f. Other _____

RECEIVED
APR 07 2003
TECH CENTER 1600/2900

2. RCE FEE REQUIRED UNDER 37 C.F.R. § 1.114

- a. Small entity status
 - i. was established in the prior nonprovisional application.
 - ii. is established herewith by the enclosed written assertion of entitlement to small entity status.
- b. A Petition and Fee for Extension of Time for ____ months up to and including ____ is enclosed herewith.
- c. A check in the amount of \$750.00 is enclosed.
- d. The Commissioner is hereby authorized to charge the required fee(s), i.e., \$____, to Deposit Account No. 20-0531.
- e. The Commissioner is hereby authorized to credit overpayments or charge any additional fees required for this submission under 37 C.F.R. §§ 1.16 and 1.17 to Deposit Account No. 20-0531.


Request For Continued Examination (RCE) Transmittal

Serial No. 09/292,217

Page 2 of 2

3. MISCELLANEOUS

- a. Return Receipt Postcard enclosed.
- b. Other: Fee Transmittal.

CORRESPONDENCE ADDRESS	SIGNATURE BLOCK
<p>Direct all correspondence to: Patent Administrator Testa, Hurwitz & Thibeault, LLP High Street Tower 125 High Street Boston, MA 02110 Tel. No.: (617) 248-7000 Fax No.: (617) 248-7100</p>	<p>Respectfully submitted,  Patrick R.H. Waller Attorney for Applicant(s) Testa, Hurwitz & Thibeault, LLP High Street Tower 125 High Street Boston, MA 02110</p>

2602286_1



PATENT
Atty. Docket No. LEX-004

#23/F
Gorgia
4/8/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Gillies

RECEIVED

SERIAL NUMBER: 09/292,217 GROUP NUMBER: 1644

APR 07 2003

FILING DATE: April 15, 1999 EXAMINER: Roark, J.

TECH CENTER 1600/2900

TITLE: ENHANCEMENT OF ANTIBODY-CYTOKINE FUSION
PROTEIN MEDiated IMMUNE RESPONSE BY CO-
ADMINISTRATION WITH ANGIOGENESIS INHIBITOR

Box RCE
Commissioner for Patents
Washington, D.C. 20231

AMENDMENT AND RESPONSE

Sir:

In response to the final Office Action for the above-identified patent application, mailed from the United States Patent and Trademark Office on January 2, 2003, Applicant respectfully submits the following Amendment and Response with a Request for Continued Examination ("RCE").

AMENDMENTS

Please enter the following amendment. In compliance with Rule 1.121, this amendment is presented below with all changes included. Another version of the amended material is attached on a separate page from the amendment and is marked up to show all the changes relative to the previous version of the material.

To the Claims

F
37. (Amended) The method of claim 36, wherein the antibody binding site further comprises a CH3 domain interposed between the CH2 domain and the interleukin-2.